Comparing MammaPrint to Oncotype Dx

(13:43)

Poster comparing Oncotype dx and Mammaprint

(4:29)

Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT

(3:56)

MammaPrint Identifies Which Breast Cancer Patients Can Bypass Chemotherapy

(1:58)

MammaPrint® - Agendia’s Risk Of Recurrence Test

(1:38)

Combining Pathology, MammaPrint and BluePrint

(1:2:)

Patient Experiences with MammaPrint®

(3:56)

Jennifer Tittensor, MD FACS Presents On Ordering MammaPrint \u0026 BluePrint on Clinically Low Risk Pts

(1:52)

MammaPrint Ultra Low Case Study By Dr. Ian Grady

(1:30)

MammaPrint genetic testing reduces chemotherapy overtreatment in breast cancer patients

(9:14)

Genomic Profiling in early stage breast cancer \u0026 Role of Mammaprint \u0026 Blueprint testing | Oncquest

(29:58)

Cost impact of unselective Mammaprint use in SA

(31:59)

Genomic testing in early breast cancer: MammaPrint \u0026 BluePrint

(2:)

Breast Cancer Test, Breast Cancer Awareness - Agendia \u0026 MammaPrint

(5:39)

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer

(1:28)

MammaPrint BluePrint Mindact Follow up data 8 years and Molecular Subtype

(1:11:28)

Jennifer Tittensor, MD FACS Presents The Benefits \u0026 Importance of MammaPrint

(2:8)

Dealing with an \

(1:56)

Jennifer Tittensor, MD FACS - Case Study - MammaPrint \u0026 BluePrint Preoperatively On Core Biopsy

(1:33)